Aquila can help you understand the immunomodulatory effects of your drug candidates within the tumour microenvironment and/or in combination with other immune modulators, efficiently progressing your route to clinic.
We have extensive in vitro immunology, pre-clinical immuno-oncology and specialist multiplex histology experience. Our suite of available immuno-oncology services and assays can be specifically tailored to your project:
- Exhausted CD4+ T Cell assay
- Human PBMC & T Cell Activation assays
- Human Mixed Lymphocyte Reactions
- Human DC, Macrophage and Co-culture assays
- T Cell Killing assay
Please get in touch to discuss how Aquila can help you with your immuno-oncology, immunology or specialist histology research needs.
The immune checkpoint space was until recently devoid of focused CRO activity. Aquila BioMedical has sought to become a driving force in this area and the result is a terrific suite of assays in both mouse and human cell systems, with multiple readouts, solid antibody benchmarking and careful controls.
Paul Rennert, CEO, SugarCone Biotech